Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 11, 2011 - Issue 8
Submit an article Journal homepage
66
Views
8
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Is the highest density of CB1 receptors in paranoid schizophrenia a correlate of endocannabinoid system functioning?

Antonio Waldo Zuardi Department of Neurosciences and Behavior, Division of Psychiatry, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Hospital das Clínicas – Terceiro Andar, Av. Bandeirantes, 3900, Ribeirão Preto, São Paulo, CEP – 14049-800, Brazil; INCT Translational Medicine, São Paulo, Brazil;[email protected]
,
Fransisco Silveira Guimarães Department of Pharmacology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Brazil; Department of Pharmacology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Brazil
,
Jaime Eduardo C Hallak Department of Neurosciences and Behavior, Division of Psychiatry, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Hospital das Clínicas – Terceiro Andar, Av. Bandeirantes, 3900, Ribeirão Preto, São Paulo, CEP – 14049-800, Brazil; INCT Translational Medicine, São Paulo, Brazil; Department of Neurosciences and Behavior, Division of Psychiatry, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Hospital das Clínicas – Terceiro Andar, Av. Bandeirantes, 3900, Ribeirão Preto, São Paulo, CEP – 14049-800, Brazil; INCT Translational Medicine, São Paulo, Brazil
&
José Alexandre S Crippa Department of Neurosciences and Behavior, Division of Psychiatry, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Hospital das Clínicas – Terceiro Andar, Av. Bandeirantes, 3900, Ribeirão Preto, São Paulo, CEP – 14049-800, Brazil; INCT Translational Medicine, São Paulo, Brazil; Department of Neurosciences and Behavior, Division of Psychiatry, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Hospital das Clínicas – Terceiro Andar, Av. Bandeirantes, 3900, Ribeirão Preto, São Paulo, CEP – 14049-800, Brazil; INCT Translational Medicine, São Paulo, Brazil
Pages 1111-1114 | Published online: 09 Jan 2014

References

  • Dean B, Sundram S, Bradbury R, Scarr E, Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience103, 9–15 (2001).
  • Zavitsanou K, Garrick T, Huang X-F. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry28, 355–360 (2004).
  • Newell KA, Deng C, Huang X-F. Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp. Brain Res.172, 556–560 (2006).
  • Eggan SM, Hashimoto T, Lewis DA. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch. Gen. Psychiatry65, 772–784 (2008).
  • Koethe D, Llenos IC, Dulay JR et al. Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J. Neural Transm.114, 1055–1063 (2007).
  • Dalton VS, Long LE, Weickert CS, Zavitsanou K. Paranoid schizophrenia is characterized by increased CB(1) receptor binding in the dorsolateral prefrontal cortex. Neuropsychopharmacology36(8), 1620–1630 (2011).
  • Ceccarini J, De Hert M, van Winkel R, Koethe D, Bormans G, Leweke M et al.In vivo PET imaging of cerebral type 1 cannabinoid receptor availability in patients with schizophrenia. Schizophrenia Res.117, 170 (2010).
  • Wong DF, Kuwabara H, Horti AG et al. Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophreniaby the novel PET radioligand [11C]OMAR. Neuroimage52, 1505–1513 (2010).
  • Giuffrida A, Leweke FM, Gerth CW et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology29, 2108–2114 (2004).
  • Dalton VS, Wang H, Zavitsanou K. HU210-induced downregulation in cannabinoid CB1 receptor binding strongly correlates with body weight loss in the adult rat. Neurochem. Res.34, 1343–1353 (2009).
  • Vigano D, Guidali C, Petrosino S, Realini N, Rubino T, Di Marzo V, Parolaro D. Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. Int. J. Neuropsychopharmacol.12(5), 599–614 (2009).
  • Fernandez-Espejo E, Viveros M-P, Núnez L, Ellenbroek BA, Fonseca FR. Role of cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology206, 531–549 (2009).
  • Brady AM, O’Donnell P. Dopaminergic modulation of prefrontal cortical input to nucleus accumbens neurons in vivo. J. Neurosci.24(5), 1040–1049 (2004).
  • Geldwert D, Norris JM , Feldman IG, Schulman JJ, Joyce MP, Rayport S. Dopamine presynaptically and heterogeneously modulates nucleus accumbens medium-spiny neuron GABA synapses in vitro. BMC Neurosci.7, 53 (2006).
  • Jones DL, Mogenson GJ. Nucleus accumbens to globus pallidus GABA projection: electrophysiological and iontophoretic investigations. Brain Res.188, 193–105 (1980).
  • Meltzer HY, Arvanitis L, Bauer D, Rein W. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am. J. Psychiatry161, 975–984 (2004).
  • Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz. J. Med. Biol. Res.39(4), 421–429 (2006).
  • Leweke FM, Koethe D, Pahlisch F et al. Antipsychotic effects of cannabidiol. Eur. Psychiatry24(Suppl. 1), 207 (2009).
  • Bisogno T, Hanus L, De Petrocellis L et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol.134(4), 845–852 (2001).
  • Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1A receptors. Neurochem. Res.30, 1037–1043 (2005).
  • Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev. Bras. Psiquiatr.30, 271–280 (2008).
  • Koethe D, Giuffrida A, Schreiber D et al. Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br. J. Psychiatry194(4), 371–372 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.